Price
No data yet.
Social Signal Score
Revenue
$1.39MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Harry Simeonidis
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 59
- Beta
- 4.49
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -9.76
Financials
Revenue
$1.39MNet Income
$-2.66MEBITDA
$-2.45MFree Cash Flow
$-2.75MEPS (diluted)
$-0.86Shares Outstanding (diluted)
3.10M+89958.4%Operating Expenses
$3.41MCash & Debt
$5.93MReturn of Capital
$0.00Revenue by Segment (annual)
$578.6KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2026 | $4.22M | $-12.43M | $-8.44 |
| 2025 | $3.05M | $-10.57M | $-20.00 |
| 2024 | $3.11M | $-10.16M | $-63.80 |
| 2023 | $1.26M | $-10.63M | $-105.80 |
| 2022 | $0.00 | $-8.31M | $-113.30 |
| 2021 | $1.98M | $-7.04M | $-162.20 |
| 2020 | $188.7K | $-3.16M | $-89.20 |
| 2019 | $0.00 | $-7.34M | $-210.10 |
| 2018 | $0.00 | $-5.02M | $-146.00 |
| 2017 | $0.00 | $-340.0K | $-9.90 |
Valuation
INBShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+2.56%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·12d ago·Neutral
Intelligent Bio Solutions Reports Record Fiscal First Quarter 2027 Revenue of $1.39 Million, Marking Sixth Consecutive Quarter of Year-Over-Year Growth Revenue up 25% year-over-year and 21% sequentially, marking third consecutive quarter above $1 million
View source ↗ - Newsglobenewswire.com·18d ago·Positive
Intelligent Bio Solutions to Present at the Webull Biotech Webinar on November 12 NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced that management will present at the Webull Biotech Webinar on Thursday, November 12, 2026. Webull Biotech Webinar Date and Time: Thursday, November 12, 2026, at 2:00 P.M.
View source ↗ - Newsseekingalpha.com·59d ago·Neutral
Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript Intelligent Bio Solutions Inc. (INBS) Discusses FDA 510(k) Submission and Progress of Intelligent Fingerprinting Drug Screening System Transcript
View source ↗ - Newsglobenewswire.com·73d ago·Negative
Intelligent Bio Solutions to Host Virtual Fireside Chat on September 24th at 4:30 p.m. ET Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S. Management to discuss FDA 510(k) submission, clinical data, and commercial progress outside the U.S.
View source ↗ - Newsglobenewswire.com·74d ago·Negative
… Intelligent Fingerprinting Drug Screening System, Seeking U.S. Market Clearance NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the submission of its 510(k) premarket notification to the U.S. Food and Drug Administration (FDA), seeking regulatory clearance of its Intelligent Fingerprinting Drug Screening System (the “Sy…
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System Multi-site clinical study delivers strong performance data for Intelligent Fingerprinting Drug Screening System
View source ↗ - Newsglobenewswire.com·95d ago·Neutral
Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth Reader installed base grew 22% year-over-year, driving a 35% increase in total consumable cartridges to over 100,000 units
View source ↗ - Newsbenzinga.com·97d ago·Neutral
Intelligent Bio Solutions Shares Surge Monday: What's Driving the Action? Shares of Intelligent Bio Solutions Inc. (NASDAQ:INBS) are surging Monday afternoon after the medical technology company announced a significant regulatory milestone for its rapid testing unit.
View source ↗
Earnings
Thu, Feb 11(in 3 months)
Consensus estimate $-1.36 per share
Typical surprise -133.3% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.86 vs $-1.31beat
- Wed, Aug 19$-1.34 vs $-1.58beat
- Tue, May 12$-1.80 vs $1.40miss
- Thu, Feb 12$-2.82 vs $0.40miss
- Thu, Nov 13$-3.50 vs $-1.50miss
- Fri, Aug 15$-3.60 vs $-1.20miss
Estimates and results for INBS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by INBS officers and directors.
- Bought
- $67k
- Sold
- —
8 trades
0 trades
- Towers Christopherbought
- Towers Christopherbought
- Towers Christopherbought
- Sakiris Spiro Kevinbought
- Sakiris Spiro Kevinbought
- Sakiris Spiro Kevinbought
- Simeonidis Harrybought
- Simeonidis Harrybought
18 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in INBS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
